Idorsia Pharmaceuticals Ltd. has described C-C chemokine receptor type 6 (CCR6) antagonists reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
Researchers at China Welfare Institute International Peace Maternity and Child Health Hospital and East China University of Science & Technology have divulged azaphenothiazine derivatives reported to be useful for the treatment of endometrial cancer.
The University of Vermont has identified ADCYAP receptor type I (PAC1 receptor) antagonists reported to be useful for the treatment of pain, eating, neurological and stress disorders, substance abuse and dependency.
Nerve growth factor (NGF) actions are involved in pain perception and mediated via the tyrosine kinase TrkA (tropomyosin receptor kinase A) in neural cells. Mutations in the gene encoding for TrkA cause hereditary sensory and autonomic neuropathy type IV (HSAN IV), a rare autosomal recessive disorder characterized by loss of responses to noxious stimuli, anhidrosis and cognitive impairment. Until now, appropriate animal models to study the mechanisms underlying HSAN IV were missing.
A proof of concept of ex vivo genetic modification of cells from patients and their transplantation in mice has demonstrated, for the first time, the therapeutic possibilities of prime editing in sickle cell disease (SCD).
Previous studies have shown that ovarian cancer (OC) has strong tumor heterogeneity, resulting in high recurrence and metastasis rates. In recently published work, researchers from Capital Medical University (CMU) applied single-cell transcriptomics to identify metastasis-associated cell clusters and key genes involved in OC metastasis.
Macrophages are specialized immune cells that can either stimulate or inhibit inflammation. Studies in mice suggest that phosphoinositide 3-kinase γ (PI3Kγ), a key mediator in macrophage signaling pathways predominantly expressed in myeloid cells, may promote immune suppression both in inflammation and in the tumor microenvironment.
RSS
